Shopping Cart 0
Cart Subtotal
USD 0

Medicenna Therapeutics Corp (MDNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company. The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132. Medicenna also offers clinical trial services. The company develops cytokines to deliver cell killing payloads to the bulk tumor, tumor microenvironment (TME), and cancer stem cells (CSC). It offers products in therapeutic areas including CNS cancers in glioblastoma multiforme, brain metastasis, padiatric gliloma, blood cancers, solid tumors, and bladder cancers. The company has operations in Canada and the US. Medicenna is headquartered in Toronto, Ontario, Canada.

Medicenna Therapeutics Corp (MDNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10

Licensing Agreements 11

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11

Equity Offering 12

Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12

Acquisition 13

A2 Acquisition Acquires Medicenna Therapeutics 13

Medicenna Therapeutics Corp-Key Competitors 14

Medicenna Therapeutics Corp-Key Employees 15

Medicenna Therapeutics Corp-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Recent Developments 17

Financial Announcements 17

Aug 13, 2018: Medicenna announces first quarter fiscal 2019 financial results 17

Jun 27, 2018: Medicenna Reports March 31, 2018 Year-End Results 19

Feb 12, 2018: Medicenna Reports Third Quarter Fiscal 2018 Financial Results 21

Nov 13, 2017: Medicenna Reports Second Quarter Fiscal 2018 Financial Results 23

Aug 09, 2017: Medicenna Reports First Quarter Fiscal 2018 Financial Results 25

Jun 16, 2017: Medicenna Announces March 31, 2017 Year End Results 26

Corporate Communications 28

Oct 18, 2017: Medicenna Announces Trading on the OTCQX Best Market in the United States 28

Sep 21, 2017: Medicenna Appoints Dr. William Li to Board of Directors 29

Jul 17, 2017: Medicenna Bolsters Management Team 30

May 25, 2017: Medicenna Therapeutics Opens the Market 31

Mar 08, 2017: Medicenna shares resume trading under the symbol "MDNA" 32

Jan 18, 2017: Medicenna Further Strengthens Management Team 33

Jan 17, 2017: Medicenna Announces Additions to the Board of Directors 34

Clinical Trials 35

Jun 08, 2017: Medicennas Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology 35

Apr 20, 2017: Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017 36

Apr 13, 2017: Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11

Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12

A2 Acquisition Acquires Medicenna Therapeutics 13

Medicenna Therapeutics Corp, Key Competitors 14

Medicenna Therapeutics Corp, Key Employees 15

Medicenna Therapeutics Corp, Subsidiaries 16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Medicenna Therapeutics Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company. The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132. Medicenna also offers clinical trial services. The company develops cytokines to deliver cell killing payloads to the bulk tumor, tumor microenvironment (TME), and cancer stem cells (CSC). It offers products in therapeutic areas including CNS cancers in glioblastoma multiforme, brain metastasis, padiatric gliloma, blood cancers, solid tumors, and bladder cancers. The company has operations in Canada and the US. Medicenna is headquartered in Toronto, Ontario, Canada.

Medicenna Therapeutics Corp (MDNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10

Licensing Agreements 11

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11

Equity Offering 12

Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12

Acquisition 13

A2 Acquisition Acquires Medicenna Therapeutics 13

Medicenna Therapeutics Corp-Key Competitors 14

Medicenna Therapeutics Corp-Key Employees 15

Medicenna Therapeutics Corp-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Recent Developments 17

Financial Announcements 17

Aug 13, 2018: Medicenna announces first quarter fiscal 2019 financial results 17

Jun 27, 2018: Medicenna Reports March 31, 2018 Year-End Results 19

Feb 12, 2018: Medicenna Reports Third Quarter Fiscal 2018 Financial Results 21

Nov 13, 2017: Medicenna Reports Second Quarter Fiscal 2018 Financial Results 23

Aug 09, 2017: Medicenna Reports First Quarter Fiscal 2018 Financial Results 25

Jun 16, 2017: Medicenna Announces March 31, 2017 Year End Results 26

Corporate Communications 28

Oct 18, 2017: Medicenna Announces Trading on the OTCQX Best Market in the United States 28

Sep 21, 2017: Medicenna Appoints Dr. William Li to Board of Directors 29

Jul 17, 2017: Medicenna Bolsters Management Team 30

May 25, 2017: Medicenna Therapeutics Opens the Market 31

Mar 08, 2017: Medicenna shares resume trading under the symbol "MDNA" 32

Jan 18, 2017: Medicenna Further Strengthens Management Team 33

Jan 17, 2017: Medicenna Announces Additions to the Board of Directors 34

Clinical Trials 35

Jun 08, 2017: Medicennas Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology 35

Apr 20, 2017: Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017 36

Apr 13, 2017: Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Medicenna Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Medicenna Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Medicenna Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10

Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 11

Medicenna Therapeutics Raises USD3 Million in Private Placement of Shares 12

A2 Acquisition Acquires Medicenna Therapeutics 13

Medicenna Therapeutics Corp, Key Competitors 14

Medicenna Therapeutics Corp, Key Employees 15

Medicenna Therapeutics Corp, Subsidiaries 16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Medicenna Therapeutics Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.